Begin typing your search above and press return to search.
EPUB Before Print

FULL TEXT

ARTICLE
Invasive Fungal Infections With Good Survival Following Liver Transplant: A Single-Center Experience From a Developing Country

Objectives: Invasive fungal infection following liver transplant is considered as one of the importantfactors influencing morbidity and mortality amongliver transplant recipients. The aim of the present study was to describe the prevalence of invasive fungal infections and their predisposing factors in a single-center cohort of patients who received liver transplant.

Materials and Methods: For this study, 250 adult patients undergoing orthotopic liver transplant between March 2010 and March 2015 were enrolled. All patients were followed prospectively for infections.

Results: The diagnosis of invasive fungal infection was made in 15 patients (6%). One patient had 2 episodes of fungal infection, and reoperation was performed for 3 patients. Invasive aspergillosis developed in 8 patients (53.3%), followed by Candida species infection in 3 patients (20%) and cryptococcosis in 2 patients (13.3%). The main predisposing factors were renal failure (12/15) and positive history of rejection (11/15). Other risk factors for development of invasive fungal infections were choledochojejunostomy in 3 patients (20%), bile leaks in 3 patients (20%), and pretransplant steroid use in 2 patients (11.8%). Two patients (13.3%) died due to invasive fungal infections.

Conclusions: In this single-center series of liver transplant recipients, the incidence of invasive fungal infections was relatively low, probably due to the universal prophylaxis with fluconazole and limited use of the broad-spectrum antibiotics. Early diagnosis and treatment of invasive fungal infections could lead to a better prognosis for liver transplant recipients with invasive fungal infections.


Key words : Antifungal prophylaxis, Cryptococcosis, Invasive aspergillosis, Iran, Mortality with candidiasis

Introduction

Over the past few decades, major advances have been made in different aspects of the transplant field such as surgical techniques, posttransplant care, immu­nosuppressive agents, and antimicrobial regimens.1 However, infectious complications are still considered as major causes of morbidity and mortality in liver transplant recipients. The frequency of infection in liver transplant recipients is higher than in other transplant recipients due to manipulation of the hepatobiliary system. Bacterial infections are the most common type of infections after liver transplant. However, invasive fungal infections (IFI) are also common and are associated with significant morbidity and mortality among liver transplant recipients. Prior to the admin­istration of antifungal prophylaxis, the occurrence of IFIs had been reported in up to 42% of liver transplant recipients.2-4 Moreover, death with any underlying cause occurred in 25% to 81% of patients diagnosed with IFIs, of which 72% of deaths was attributed to IFIs.5,6

Previous studies have suggested several pre­operative and postoperative risk factors for IFIs. Prolonged surgical time, high volume of blood transfusion during surgery, early surgical reexploration, and choledochojejunostomy are surgical parameters associated with IFIs.2,5,7,8 Preoperative factors for IFIs include prolonged intensive care unit stay, antibiotics used for spontaneous bacterial peritonitis, hepatic artery thrombosis, retransplant, and fulminant hepatic failure. Candida species colonization early after transplant, bile leaks, significant renal dysfunction, and Cytomegalovirus (CMV) reactivation are perioperative risk factors for IFIs, according to previously reported studies.2-5,7

Despite the decreased trend in incidence of IFIs since the mid-1990s, fungal infections still pose a significant burden to liver transplant recipients. According to recently published studies, the incidence of IFIs ranges from 5% to 20% of recipients.9-13 Therefore, the aim of this study is to investigate the current status of IFI in the early period after liver transplant in a medium-volume liver transplant center.

Materials and Methods

Study population
The medical records of 250 patients who received liver transplant at Imam Khomeini Hospital, Tehran, Iran, from March 2010 to March 2015 were retro­spectively reviewed. All transplanted livers were from deceased donors who were medical and legally dead. All liver transplant recipients underwent routine follow-up. Data obtained from medical records included demographic features, underlying diseases, transplant type, clinical characteristics, microbiologic screening results, potential risk factors, types and sites of infection, and medical and surgical complications during the study period.

Fifteen patients were diagnosed with IFI according to the criteria proposed by the European Organization on Research and Treatment in Cancer and the Mycoses Study Group.14 Two episodes of IFI had occurred in one patient. The day of the first microbiologic documentation of infection was considered as the day of diagnosis. For cases with postmortem diagnoses, the day of death was considered as the day of diagnosis.

Microbiologic diagnosis
Pleural and peritoneal fluid, bronchoalveolar lavage, and/or lumbar puncture samples of patients were evaluated for smear and culture for fungi. Aspergillus galactomannan antigen was measured in the serum samples. Moreover, pan-fungal polymerase chain reac­tion assays were performed on some of the samples.

Surgical methods and prophylactic regimens
For transplant procedures, most patients underwent the piggy-back technique; however, in some patients, the standard technique was considered. All liver transplant recipients received antibiotic prophylaxis perioperatively until 48 hours after surgery. The antibiotic regimen included piperacillin tazobactam or ampicillin sulbactam for patients with or without history of recent hospitalization or prolonged antibiotic therapy, respectively. All patients received fluconazole (100 mg twice daily) as antifungal prophylaxis in the early period after transplant, until prednisone dose had been decreased to 15 mg/day. Surveillance for fungal colonization in recipients is not routinely performed in our center. Acyclovir and sulfamethoxazole-trimethoprim are used as universal prophylaxis for herpes simplex virus infection and Pneumocystis jiroveci, respectively, in our center. For prevention of CMV infection, we use preemptive therapy for low-risk to moderate-risk patients. Primary prophylaxis with ganciclovir is used for high-risk recipients (including donor-positive/recipient-negative patients and retransplant patients). The diagnosis of CMV infection was made based on detection of viral antigen (CMV PP65) in peripheral blood leukocytes.

Immunosuppression included administration of 1 g methylprednisone simultaneously when the liver entered the body, with gradual tapering day by day. Mycophenolate mofetil and tacrolimus were initiated on postoperative days 1 and 2, respectively.

Statistical analyses
Continuous variables were examined for normal distribution using the Shapiro-Wilks test. For independent numeric variables, t test was used; for independent nominal variables, the Fisher exact test or Mann-Whitney U test was used as indicated. Statistical significance was defined as P < .05. Data were analyzed using SPSS version 23.0 (SPSS Inc.; Chicago, IL, USA).

Results

Clinical characteristics of patients
The characteristics of the 15 patients are summarized in Table 1. Ten patients were male, and the mean age of the patients was 46.4 years (range, 23-62 y). Patients were followed for 27.1 ± 22.2 months. The most common indication for liver transplant was cryptogenic cirrhosis in 5 patients (33.3%), followed by autoimmune hepatitis in 3 patients (20%), hepatitis C virus infection in 2 patients (13.3%), and hepatitis B virus in 2 patients (13.3%). Hepatocellular carcinoma and nonalcoholic steatohepatitis were diagnosed in 1 patient each. The Model for End-Stage Liver Disease (MELD) score of the patients was 20.7 ± 3.01, ranging from 16 to 25.

Invasive aspergillosis developed in 8 patients (53.3%), followed by Candida species infection in 3 patients (20%) and cryptococcosis in 2 patients (13.3%). Aspergillus fumigatus was isolated in 1 patient; the remaining cases were diagnosed on the basis of either serologic or pathologic findings. The organism responsible for infection was not identified in 3 patients; diagnoses of IFIs for these patients were made based on radiologic findings and high clinical suspicion.

All patients with IFI underwent deceased-donor liver transplant. The median time of diagnosis was 32 days after transplant (range, 3-588 d). Clinical manifestations, diagnostic criteria, and treatment regimens of patients are shown in Table 1. Liposomal amphotericin B was the most common antifungal agent administered for IFIs (13 patients), followed by fluconazole (4 patients) and voriconazole (4 patients). The main predisposing factors were renal failure (12/15) and positive history of rejection (11/15). Other risk factors for development of IFIs were choledochojejunostomy in 3 patients (20%), bile leaks in 3 patients (20%), and pretransplant steroid use in 2 patients (11.8%). Two patients (13.3%) died due to IFIs.

Discussion

Invasive fungal infections are major problems in organ transplant recipients. The highest incidence and the greatest mortality from fungal infection occur in liver transplant recipients.15 Our study revealed that, in our institution, the overall incidence of IFIs was 6% and the mortality rate due to IFI was 0.8%.

In a study from Raghuram and associates that assessed the occurrence of IFIs and their associated factors in 502 liver transplant recipients, 12% of liver transplant recipients were diagnosed with IFIs.16 In another study of the epidemiology of IFI after liver transplant in Japanese liver transplant recipients, the overall rate of IFI was 5.4% and the mortality rate among patients with IFIs was 80%.17 According to previous studies, the most common IFI diagnosed in solid-organ transplant recipients is candidiasis, accounting for 53% of infections.11 However, the rate of diagnosed candidiasis was 20% in our patients with IFIs. Low prevalence of candidiasis in our patients could be explained by universal fungal prophylaxis with high dose of fluconazole in liver transplant recipients in our center and the lower incidence of fluconazole-resistant Candida species infections.

Almost all of our patients had at least one of the risk factors associated with IFIs highlighted in previous studies. According to the American Society of Transplantation Infectious Diseases Community of Practice and the Infectious Diseases Society of America clinical practice guidelines, retransplant, reoperation, and renal failure are among the major risk factors for IFIs following liver transplant.18 In our cohort of patients diagnosed with IFIs, renal failure occurred in the majority of them and 1 patient underwent retransplant. Other recently suggested risk factors for IFIs in the posttransplant period include pretransplant fungal colonization,16 high MELD score,16 low dose of daily prophylactic fluconazole (< 200 mg),16 steroid use before liver transplant,17 blood stream infection within 90 days after liver transplant,17 reoperation within 90 days after liver transplant,17 and living-donor liver transplant.17 History of rejection, CMV infection, and choledochojejunostomy were the 3 major risk factors of IFIs in the liver transplant recipients in our study; these factors compare to those mentioned in previous studies.2,7,19 Our results are in concordance with previously defined risk factors for IFIs such as bile leaks and choledochojejunostomy.2

Interestingly, our survival rate following IFIs was significantly lower than that shown in previous studies. In a study from Nagao and associates,17 only 20% of patients diagnosed with IFIs survived; however, only 2 patients in our series died due to IFIs. All of our patients underwent deceased-donor liver transplant, which is in contrast to 90% living donors in the Japanese center study. Therefore, we hypothesized that living-donor transplant could result in a significant difference in mortality rate. In another study, conducted in the United States, in which medical records of 502 patients who underwent deceased-donor liver transplant were retrospectively reviewed, the 1-year patient survival rate was 41% in patients with IFI.16 In another study, Singh and associates prospectively followed 40 transplant recipients diagnosed with invasive aspergillosis. Of these, 50% of the infections were late-onset. The investigators found that mortality rate attributable to invasive aspergillosis was 15% in patients with early-onset infection and 35% in those with late onset infection.20 In a study from Husain and colleagues, the mortality rate was 36.1% in 35 liver transplant recipients with invasive candidiasis.5 Lower MELD score and early onset of antifungal treatment after the onset of symptoms are other reasons for our low rate of mortality in this study. In addition, we may have underestimated the incidence and mortality of IFIs due to the retrospective design of this study and some episodes of IFIs could have been missed, especially among deceased recipients with undiagnosed causes of death.

Our results were significantly limited by several important factors. Similar to other retrospective studies, it is difficult to establish a precise cause-effect relationship between risk factors and occurrence of IFIs. Furthermore, our criteria for diagnosis of IFIs were radiologic findings in a few patients, and we were not able to make a definite diagnosis based on serologic findings or tissue sampling.

Conclusions

Our study revealed that the incidence of IFIs in Iranian liver transplant recipients is relatively low and is comparable with other centers. Moreover, our mortality rate was significantly lower than that shown in previous studies. Early diagnosis and treatment of IFIs could lead to a better prognosis of liver transplant recipients with IFIs. However, larger prospective studies are recommended to strengthen the current evidence.


References:

  1. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med. 2007;357(25):2601-2614.
    CrossRef - PubMed
  2. Collins LA, Samore MH, Roberts MS, et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis. 1994;170(3):644-652.
    CrossRef - PubMed
  3. Briegel J, Forst H, Spill B, et al. Risk factors for systemic fungal infections in liver transplant recipients. Eur J Clin Microbiol Infect Dis. 1995;14(5):375-382.
    CrossRef - PubMed
  4. Kusne S, Dummer JS, Singh N, et al. Infections after liver transplantation. An analysis of 101 consecutive cases. Medicine (Baltimore). 1988;67(2):132-143.
    CrossRef - PubMed
  5. Husain S, Tollemar J, Dominguez EA, et al. Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study. Transplantation. 2003;75(12):2023-2029.
    CrossRef - PubMed
  6. Rabkin JM, Oroloff SL, Corless CL, et al. Association of fungal infection and increased mortality in liver transplant recipients. Am J Surg. 2000;179(5):426-430.
    CrossRef - PubMed
  7. Patel R, Portela D, Badley AD, et al. Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation. Transplantation. 1996;62(7):926-934.
    CrossRef - PubMed
  8. Singh N, Avery RK, Munoz P, et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis. 2003;36(1):46-52.
    CrossRef - PubMed
  9. Pacholczyk M, Lagiewska B, Lisik W, Wasiak D, Chmura A. Invasive fungal infections following liver transplantation - risk factors, incidence and outcome. Ann Transplant. 2011;16(3):14-16.
    CrossRef - PubMed
  10. Singh N. Fungal infections in the recipients of solid organ transplantation. Infect Dis Clin North Am. 2003;17(1):113-134, viii.
    CrossRef - PubMed
  11. Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis. 2010;50(8):1101-1111.
    CrossRef - PubMed
  12. Saliba F, Delvart V, Ichai P, et al. Fungal infections after liver transplantation: outcomes and risk factors revisited in the MELD era. Clin Transplant. 2013;27(4):E454-E461.
    CrossRef - PubMed
  13. Singh N, Husain S, AST Infectious Diseases Community of Practice. Invasive aspergillosis in solid organ transplant recipients. Am J Transplant. 2009;9 Suppl 4:S180-S191.
    CrossRef - PubMed
  14. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813-1821.
    CrossRef - PubMed
  15. Neofytos D, Fishman JA, Horn D, et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis. 2010;12(3):220-229.
    CrossRef - PubMed
  16. Raghuram A, Restrepo A, Safadjou S, et al. Invasive fungal infections following liver transplantation: incidence, risk factors, survival, and impact of fluconazole-resistant Candida parapsilosis (2003-2007). Liver Transpl. 2012;18(9):1100-1109.
    CrossRef - PubMed
  17. Nagao M, Fujimoto Y, Yamamoto M, et al. Epidemiology of invasive fungal infections after liver transplantation and the risk factors of late-onset invasive aspergillosis. J Infect Chemother. 2016;22(2):84-89.
    CrossRef - PubMed
  18. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(5):503-535.
    CrossRef - PubMed
  19. George MJ, Snydman DR, Werner BG, et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. Am J Med. 1997;103(2):106-113.
    CrossRef - PubMed
  20. Singh N, Limaye AP, Forrest G, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation. 2006;81(3):320-326.
    CrossRef - PubMed


DOI : 10.6002/ect.2019.0010


PDF VIEW [173] KB.

From the 1Liver Transplantation Research Center, the 2Department of Hepatobiliary and Liver Transplantation, and the 3Department of Infectious Disease, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
Acknowledgements: This research has been supported by Tehran University of Medical Sciences and Health Services grant number 96-02-205-35142. The authors have no conflicts of interest to disclose.
Corresponding author: Zahra Ahmadinejad, Department of Infectious Disease, Imam Khomeini Hospital Complex, Keshavarz Blvd, Tehran, Iran
Phone: +02166581598
E-mail: ahmadiz@tums.ac.ir